Last reviewed · How we verify
Methylphenidate extended-release; Atomoxetine
Methylphenidate extended-release; Atomoxetine is a Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine) Small molecule drug developed by McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.
Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity, while atomoxetine is a selective norepinephrine reuptake inhibitor.
Methylphenidate extended-release is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD), as indicated by ClinicalTrials.gov. It works by inhibiting the sodium-dependent dopamine transporter, a mechanism of action supported by ChEMBL.
At a glance
| Generic name | Methylphenidate extended-release; Atomoxetine |
|---|---|
| Sponsor | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. |
| Drug class | Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine) |
| Target | Dopamine transporter and norepinephrine transporter (methylphenidate); norepinephrine transporter (atomoxetine) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Methylphenidate blocks the reuptake of dopamine and norepinephrine at the presynaptic terminal, increasing their availability in the synaptic cleft. Atomoxetine selectively inhibits the norepinephrine transporter, leading to increased norepinephrine levels in the prefrontal cortex and other brain regions. Together, these mechanisms enhance attention, focus, and impulse control in patients with ADHD.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Common side effects
- Insomnia
- Decreased appetite
- Headache
- Nausea
- Abdominal pain
- Dizziness
- Tachycardia
Key clinical trials
- Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits (PHASE2)
- Interventions for Children With Attention and Reading Disorders (PHASE4)
- A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors
- Treatment Drop-out and Missed Appointments Among Adults With ADHD
- Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder (PHASE4)
- Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylphenidate extended-release; Atomoxetine CI brief — competitive landscape report
- Methylphenidate extended-release; Atomoxetine updates RSS · CI watch RSS
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. portfolio CI
Frequently asked questions about Methylphenidate extended-release; Atomoxetine
What is Methylphenidate extended-release; Atomoxetine?
How does Methylphenidate extended-release; Atomoxetine work?
What is Methylphenidate extended-release; Atomoxetine used for?
Who makes Methylphenidate extended-release; Atomoxetine?
What drug class is Methylphenidate extended-release; Atomoxetine in?
What development phase is Methylphenidate extended-release; Atomoxetine in?
What are the side effects of Methylphenidate extended-release; Atomoxetine?
What does Methylphenidate extended-release; Atomoxetine target?
Related
- Drug class: All Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine) drugs
- Target: All drugs targeting Dopamine transporter and norepinephrine transporter (methylphenidate); norepinephrine transporter (atomoxetine)
- Manufacturer: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing